检索结果-南通市图书馆

Interaction between diet and genetics in patients with inflammatory bowel disease

World Journal of Gastroenterology 2024年第12期30卷 1644-1650页

作者： Daniéla Oliveira Magro ligia yukie s.s.aki Júlio Maria Fonseca Chebli Department of surgery Faculty of Medical SciencesState University of Campinas(UNICAMP)Campinas 13083-970São PauloBrazil Department of Internal Medicine Medical SchoolSao Paulo State University(UNESP)Botucatu 18618-687São PauloBrazil Department of Medicine University Hospital of the Federal University of Juiz de ForaUniversity of Juiz de Fora School of MedicineJuiz de Fora 36036-247Minas GeraisBrazil

In this editorial,we comment on the article by Marangoni et al,published in the recent issue of the World Journal of Gastroenterology 2023;29:5618-5629,about“Diet as an epigenetic factor in inflammatory bowel disease”.The authors emphasized the role of diet,especially the interaction with genetics,in promoting the inflam-matory process in inflammatory bowel disease(IBD)patients,focusing on DNA methylation,histone modifications,and the influence of *** this editorial,we explore the interaction between genetics,gut microbiota,and diet,in an only ***,we provided dietary recommendations for patients with *** Western diet,characterized by a low fiber content and deficiency the micronutrients,impacts short-chain fatty acids production and may be related to the pathogenesis of *** the other hand,the consumption of the Mediter-ranean diet and dietary fibers are associated with reduced risk of IBD flares,particularly in Crohn’s disease(CD)*** to the dietary guidance from the International Organization for the study of Inflammatory Bowel Diseases(IOIBD),the regular consumption of fruits and vegetables while reducing the consumption of saturated,trans,dairy fat,additives,processed foods rich in maltodextrins,and artificial sweeteners containing sucralose or saccharine is recommended to CD *** patients with ulcerative colitis,the IOIBD recommends the increased intake of natural sources of omega-3 fatty acids and follows the same restrictive recommendations aimed at CD patients,with the possible inclusion of red *** conclusion,IBD is a complex and hetero-geneous disease,and future studies are needed to elucidate the influence of epigenetics on diet and microbiota in IBD patients.

关键词： Diet Genetics MicroRNAs Gastrointestinal microbiome Inflammatory bowel diseases Crohn’s disease

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Fecal calprotectin and endoscopic scores: The cornerstones in clinical practice for evaluating mucosal healing in inflammatory bowel disease

引用

World Journal of Gastroenterology 2024年第24期30卷 3022-3035页

作者： Marcia Henriques de Magalhães Costa ligia yukie s.s.aki Júlio Maria Fonseca Chebli Department of Clinical Medicine Fluminense Federal UniversityRio de Janeiro 24210-200Brazil Department of Internal Medicine Medical SchoolSão Paulo State University(Unesp)Botucatu 18618-686São PauloBrazil Division of Gastroenterology Department of MedicineUniversity Hospital of The Federal University of Juiz de ForaUniversity of Juiz de Fora School of MedicineJuiz de Fora 36036-247Minas GeraisBrazil

Managing inflammatory bowel disease(IBD)is becoming increasingly complex and personalized,considering the advent of new advanced therapies with distinct mechanisms of *** mucosal healing(MH)is a pivotal therapeutic goal in IBD management and can prevent IBD progression and reduce flares,hospitalization,surgery,intestinal damage,and colorectal *** proactive disease and therapy assessment is essential to achieve better control of intestinal inflammation,even if subclinical,to alter the natural course of *** monitoring of fecal calprotectin(FC)levels and interval endoscopic evaluations are cornerstones for evaluating response/remission to advanced therapies targeting IBD,assessing MH,and detecting subclinical ***,we comment on the article by Ishida et al Moreover,this editorial aimed to review the role of FC and endoscopic scores in predicting MH in patients with ***,we intend to present some evidence on the role of these markers in future targets,such as histological and transmural *** prospective multicenter studies with a stricter MH criterion,standardized endoscopic and histopathological analyses,and virtual chromoscopy,potentially including artificial intelligence and other biomarkers,are desired.

关键词： Fecal calprotectin Endoscopic scores Mucosal healing Histological healing Ulcerative colitis Inflammatory bowel diseases

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

MicroRNAs in inflammatory bowel disease:What do we know and what can we expect?

引用

World Journal of Gastroenterology 2024年第16期30卷 2184-2190页

作者： Ellen Cristina souza de Oliveira Ana Elisa Valencise Quaglio Thais Gagno Grillo Luiz Claudio Di stasi ligia yukie s.s.aki Department of Internal Medicine Medical SchoolSão Paulo State University(Unesp)Botucatu 18618-686São PauloBrazil Verum Ingredients Botucatu Technology ParkBotucatu 18605-525São PauloBrazil Department of Biophysics and Pharmacology Institute of BiosciencesSão Paulo State University(Unesp)Botucatu 18618-689São PauloBrazil

MicroRNAs(miRNAs),small non-coding RNAs composed of 18–24 nucleotides,are potent regulators of gene expression,contributing to the regulation of more than 30%of protein-coding *** that miRNAs are regulators of inflammatory pathways and the differentiation of intestinal epithelial cells,there is an interest in exploring their importance in inflammatory bowel disease(IBD).IBD is a chronic and multifactorial disease of the gastrointestinal tract;the main forms are Crohn's disease and ulcerative *** studies have investigated the dysregulated expression of miRNAs in IBD,demonstrating their important roles as regulators and potential biomarkers of this *** editorial presents what is known and what is expected regarding miRNAs in *** the important regulatory roles of miRNAs in IBD are clearly established,biomarkers for IBD that can be applied in clinical practice are lacking,emphasizing the importance of further *** regarding the influence of miRNAs on the inflammatory process and the exploration of their role in gene regulation are expected to provide a basis for the use of miRNAs not only as potent biomarkers in IBD but also as therapeutic targets for the control of inflammatory processes in personalized medicine.

关键词： MicroRNAs Inflammatory bowel disease Crohn’s disease Ulcerative colitis Biomarker Therapy

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Corroborative Activities and Recognition Between Community Comprehensive Care Unit’s Nurses and Care Managers in supporting Discharge of Elderly from Hospital - A secondary Publication

引用

Journal of Clinical and Nursing Research 2024年第4期8卷 381-392页

作者： yukie sakamoto shizuko Omote Rie Okamoto Yutaro Takahashi satomi Ikeuchi Division of Health sciences Graduate School of Medical SciencesKanazawa UniversityKanazawa 920-0934Japan Kanazawa City Community Comprehensive support Center Tobiume Kanazawa 920-0938Japan Faculty of Health sciences Institute of MedicalPharmaceutical and Health SciencesKanazawa UniversityKanazawa 920-1192Japan

Objective: The purpose of this study was to clarify the collaborative activities and mutual recognition between community comprehensive care unit nurses (Ns) and care managers (CM) in supporting the discharge of the elderly from the hospital. Methods: A total of 300 nurses working in community comprehensive care wards and 360 care managers working in B City in A Prefecture were surveyed using an anonymous self-administered questionnaire. Results: The highest percentage of responses regarding necessary collaborative activities with multiple professions in supporting hospital discharge were the same for Ns and CMs. The items regarding practice with the highest percentages were “relationship as a team” for Ns, and “user-centered awareness” for CM. While these professionals were willing to share information about their patients’ lives after discharge, the percentage of those explaining their expertise was low. It is thought that collaborative activities focusing on these aspects would lead to more appropriate discharge support.

关键词： Discharge support Community comprehensive care ward Ward nurses Care managers Collaborative activities

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Quality of care in patients with inflammatory bowel disease from a public health center in Brazil

引用

World Journal of Clinical Cases 2022年第33期10卷 12184-12199页

作者： Debora Mayumi Takamune Giovana signorelli Astolfi Cury Giulia Ferrás Giedre soares Prates Herrerias Adriana Rivera Jaqueline Ribeiro Barros Julio Pinheiro Baima Rogerio saad-Hossne ligia yukie s.s.aki Department of Internal Medicine São Paulo State University(Unesp)Medical SchoolBotucatu 18618686São PauloBrazil Research Unit Virgen Macarena University HospitalSeville 41009Spain Department of Medicine Nove de Julho UniversityBauru 17011-102São PauloBrazil Department of surgery São Paulo State University(Unesp)Medical SchoolBotucatu 18618686São PauloBrazil

BACKGROUND Inflammatory bowel diseases(IBDs)are chronic diseases that demand continuous interaction between patients and healthcare *** of care(QoC)is a factor that contributes to a patient’s adherence to treatment and its *** To evaluate QoC in patients from a single IBD reference *** This cross-sectional study included 133 patients from a single Brazilian IBD public health *** was evaluated through the QoC Through the Eyes of Patients with IBD(QUOTE-IBD)questionnaire(based on patient perspectives),which measures eight dimensions of *** compared QoC among patients with Crohn’s disease and ulcerative colitis and analyzed the clinical and psychological factors associated with QoC *** evaluations assessed disease characteristics,quality of life,anxiety,and depression *** sixty-nine patients with Crohn’s disease and 64 with ulcerative colitis were *** mean age was 37.26 years±13.05 years,and 63.91%of the patients were *** mean duration of the disease was 8.44 years±7.59 years,where most patients were in remission(70.31%of patients with ulcerative colitis and 62.32%with Crohn’s disease).The total QoC score of the sample was 8.61 years±1.31 points,indicating that the QoC provided by the center was *** to univariate logistic regression,patients with Crohn’s disease had higher satisfaction rates than those with ulcerative colitis[odds ratio(OR):2.746;95%confidence interval(CI):1.360-5.541;P=0.0048]and patients on infliximab(OR:2.175;95%CI:1.037-4.562;P=0.0398).CONCLUsION Patients from the IBD public center reported good doctor-patient relationships,but had problems related to the healthcare *** of healthcare centers is of paramount to improve QoC for the patients involved.

关键词： QUOTE-IBD questionnaire Quality of care Crohn’s disease Ulcerative colitis Inflammatory bowel disease Doctor-patient relationship

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Gut microbiota,inflammatory bowel disease and colorectal cancer

引用

World Journal of Gastroenterology 2022年第30期28卷 4053-4060页

作者： Ana Elisa Valencise Quaglio Thais Gagno Grillo Ellen Cristina souza De Oliveira Luiz Claudio Di stasi ligia yukie s.s.aki Departament of Biophysics and Pharmacology Sao Paulo State University(Unesp)Institute of BiosciencesBotucatu 18618-689Sao Paulo StateBrazil Department of Internal Medicine Sao Paulo State University(Unesp)Medical SchoolBotucatu 18618-686Sao Paulo StateBrazil

The gut microbiota is a complex community of microorganisms that inhabit the digestive tracts of humans,living in symbiosis with the ***,characterized by an imbalance between the beneficial and opportunistic gut microbiota,is associated with several gastrointestinal disorders,such as irritable bowel syndrome(IBs);inflammatory bowel disease(IBD),represented by ulcerative colitis and Crohn’s disease;and colorectal cancer(CRC).Dysbiosis can disrupt the mucosal barrier,resulting in perpetuation of inflammation and *** increase in some specific groups of harmful bacteria,such as Escherichia coli(***)and enterotoxigenic Bacteroides fragilis(ETBF),has been associated with chronic tissue inflammation and the release of pro-inflammatory and carcinogenic mediators,increasing the chance of developing CRC,following the inflammationdysplasia-cancer sequence in IBD ***,the aim of the present review was to analyze the correlation between changes in the gut microbiota and the development and maintenance of IBD,CRC,and IBD-associated *** with IBD and CRC have shown reduced bacterial diversity and abundance compared to healthy individuals,with enrichment of Firmicute sand *** bacteria are also associated with the onset and progression of CRC,such as Fusobacterium nucleatum,***,Enterococcus faecalis,streptococcus gallolyticus,and *** research can evaluate the advantages of modulating the gut microbiota as preventive measures in CRC high-risk patients,directly affecting the prognosis of the disease and the quality of life of patients.

关键词： Gut microbiota Dysbiosis Ulcerative colitis Crohn’s disease Inflammatory bowel disease Colorectal cancer

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Intestinal complications in Brazilian patients with ulcerative colitis treated with conventional therapy between 2011 and 2020

引用

World Journal of Gastroenterology 2023年第8期29卷 1330-1343页

作者： Adalberta Lima Martins Rodrigo Galhardi Gasparini ligia yukie s.s.aki Rogerio saad-Hossne Alessandra Mileni Versut Ritter Tania Biatti Barreto Taciana Marcolino Claudia Yang santos Espirito santo Health Office State Office for Pharmaceutical AssistanceEspirito Santos 29056-030Brazil Department of Gastroenterology Specialized Medical CenterMarília 17502-020Brazil Department of Gastroenterology Sao Paulo State UniversityMedical SchoolBotucatu 18618-687Brazil Real World Evidence IQVIA BrazilSao Paulo 04719-002Brazil Department of Gastroenterology Takeda Pharmaceuticals BrazilSao Paulo 04794-000Brazil

BACKGROUND This was an observational, descriptive, and retrospective study from 2011 to 2020 from the Department of Informatics of the Brazilian Healthcare system *** To describe the intestinal complications(IC) of patients with ulcerative colitis(UC) who started conventional therapies in Brazil’s public Healthcare *** Patients ≥ 18 years of age who had at least one claim related to UC 10th revision of the International statistical Classification of Diseases and Related Health Problems(ICD-10) code and at least 2 claims for conventional therapies were included. IC was defined as at least one claim of: UC-related hospitalization, procedures code for rectum or intestinal surgeries, and/or associated disease defined by ICD-10 codes(malignant neoplasia of colon, stenosis, hemorrhage, ulcer and other rectum or anus disease, megacolon, functional diarrhea volvulus, intussusception and erythema nodosum). Descriptive statistics, annual incidence, and incidence rate(IR) [per 100 patient-years(PY)] over the available follow-up period were *** In total, 41229 UC patients were included(median age, 48 years;65% women) and the median(interquartile range) follow-up period was 3.3(1.8-5.3) years. Conventional therapy used during follow-up period included: mesalazine(87%), sulfasalazine(15%), azathioprine(16%) or methotrexate(1%) with a median duration of 1.9(0.8-4.0) years. Overall IR of IC was 3.2 cases per 100 PY. Among the IC claims, 54% were related to associated diseases, 20% to procedures and 26% to hospitalizations. The overall annual incidence of IC was 2.9%, 2.6% and 2.5% in the first, second and third year after the first claim for therapy(index date), respectively. Over the first 3 years, the annual IR of UC-related hospitalizations ranged from 0.8% to 1.1%;associated diseases from 0.9% to 1.2%-in which anus or rectum disease, and malignant neoplasia of colon were the most frequently reported;and procedure events from 0.6% to 0.7%, bein

关键词： Ulcerative colitis Brazil Conventional therapy Intestinal complications Real world Public healthcare

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Intestinal complications in patients with Crohn's disease in the Brazilian public healthcare system between 2011 and 2020

引用

World Journal of Clinical Cases 2023年第14期11卷 3224-3237页

作者： ligia yukie s.s.aki Adalberta Lima Martins Rodrigo Galhardi-Gasparini Rogerio saad-Hossne Alessandra Mileni Versut Ritter Tania Biatti Barreto Taciana Marcolino Bruno Balula Claudia Yang-santos Department of Internal Medicine São Paulo State University-UNESPMedical School18618687BotucatuBrazil Department of Gastroenterology State Office for Pharmaceutical Assistance at Espírito Santo Health OfficeVitoria 29017-010Espirito SantoBrazil Department of Gastroenterology SETE–Specialized Medical CenterMarilia 17502-020Sao PauloBrazil Department of surgery São Paulo State University-UNESPMedical School18618687BotucatuBrazil Real World Evidence IQVIA Brazil04719-002Sao PauloBrazil Medical Affairs Takeda Pharmaceuticals Brazil04794-000Sao PauloBrazil Clinical Research Takeda Pharmaceuticals Brazil04794-000Sao PauloBrazil

BACKGROUND This is a secondary database study using the Brazilian public healthcare system *** To describe intestinal complications(ICs)of patients in the Brazilian public healthcare system with Crohn’s disease(CD)who initiated and either only received conventional therapy(CVT)or also initiated anti-tumor necrosis factor(anti-TNF)therapy between 2011 and *** This study included patients with CD[international classification of diseases–10th revision(ICD-10):K50.0,K50.1,or K50.8](age:≥18 years)with at least one claim of CVT(sulfasalazine,azathioprine,mesalazine,or methotrexate).IC was defined as a CD-related hospitalization,pre-defined procedure codes(from rectum or intestinal surgery groups),and/or associated disease(pre-defined ICD-10 codes),and overall(one or more type of ICs).REsULTs In the 16809 patients with CD that met the inclusion criteria,the mean follow-up duration was 4.44(2.37)*** total,14697 claims of ICs were found from 4633 *** the 1-and 5-year of follow-up,8.3%and 8.2%of the patients with CD,respectively,presented at least one IC,of which fistula(31%)and fistulotomy(48%)were the most commonly *** overall incidence rate(95%CI)of ICs was 6.8(6.5–7.04)per 100 patient years for patients using only-CVT,and 9.2(8.8–9.6)for patients with evidence of anti-TNF *** The outcomes highlighted an important and constant rate of ICs over time in all the CD populations assessed,especially in patients exposed to anti-TNF *** outcome revealed insights into the real-world treatment and complications relevant to patients with CD and highlights that this disease remains a concern that may require additional treatment strategies in the Brazilian public healthcare system.

关键词： Crohn’s disease Intestinal complications Anti-tumor necrosis factor Conventional therapy Public healthcare system

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Acute heart failure as an adverse event of tumor necrosis factor inhibitor therapy in inflammatory bowel disease:A review of the literature

引用

World Journal of Cardiology 2023年第5期15卷 217-228页

作者： Thais Gagno Grillo Caroline Ferreira da silva Mazeto Pupo silveira Ana Elisa Valencise Quaglio Renata de Medeiros Dutra Julio Pinheiro Baima silmeia Garcia Zanati Bazan ligia yukie s.s.aki Department of Internal Medicine Medical SchoolSão Paulo State UniversityBotucatuBotucatu 18618686Brazil Department of Biophysics and Pharmacology Institute of BiosciencesSão Paulo State UniversityBotucatuBotucatu 18618689Brazil

Tumor necrosis factor inhibitors(anti-TNFs)are widely used therapies for the treatment of inflammatory bowel diseases(IBD);however,their administration is not *** failure(HF),although rare,is a potential adverse event related to administration of these ***,the exact mechanism of development of HF remains ***αis found in both healthy and damaged *** effects are concentration-and receptor-dependent,promoting either cardio-protection or cardiomyocyte *** rat models with TNFαreceptor knockout showed increased survival rates,less reactive oxygen species formation,and improved diastolic left ventricle ***,clinical trials employing anti-TNF therapy to treat HF had disappointing results,suggesting abolishment of the cardioprotective properties of TNFα,making cardiomyocytes susceptible to apoptosis and ***,patients with IBD who have risk factors should be screened for HF before initiating anti-TNF *** review aims to discuss adverse events associated with the administration of anti-TNF therapy,with a focus on HF,and propose some approaches to avoid cardiac adverse events in patients with IBD.

关键词： Tumor necrosis factor inhibitors Inflammatory bowel disease Heart failure Adverse event TNFαreceptor

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Non-Hodgkin＇s Lymphoma： An Important Differential Diagnosis in Inflammatory Bowel Disease

引用

Chinese Medical Journal 2018年第11期131卷 1377-1378页

作者： Rogerio saad-Hossne Carina De Fatima De sibia Julio Pinheiro Baima ligia yukie s.s.aki Department of surgery Division of Coloproctology Botucatu Medical School Sao Paulo State University-UNESP Botucatu SP 18618-687 Brazil Department of Internal Medicine (Gastroenterology) Botucatu Medical School Sao Paulo State University-UNESP Botucatu SP 18618-687 Brazil

To the Editor： The gastrointestinal tract （GIT） is the most common extranodal location ofnon-Hodgkin＇s lymphoma, but it represents only 0.4% of primary colonic malignancies. symptoms are nonspecific and may include diarrhea, constipation, abdominal pain, weight loss, and gastrointestinal bleeding. In colon, the most common types are conventional large cell lymphoma, mucosa-associated lymphoid tissue lymphoma, and T-cell lymphoma.

关键词：

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：